mRNA Vaccine and Therapeutics Market Size and Report 2032

mRNA Vaccine and Therapeutics market size was valued at USD 7,800 million in 2018 and is projected to reach USD 46,668.48 million by 2032.

By Type (Prophylactic, Therapeutic); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa); By End-Use (Hospitals & Clinics, Research Organizations, Others); By Application (Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Others)

SKU: CR2021Report Pages: 250Category: Medical DevicesReport Format: PDF, ExcelLast Updated: May 28Author: Shweta BishtReviewed by: Deepti AgrawalPreferred on

Market Report Metrics

Revenue, 2018 -
USD 7,800 million
Forecast Year -
2032
CAGR (2018–2032)
16.93%
Report Coverage
Global

mRNA Vaccine and Therapeutics Market Overview:

The Global mRNA Vaccine and Therapeutics Market size was valued at USD 7,800.00 million in 2018 to USD 13,444.94 million in 2024 and is anticipated to reach USD 46,668.48 million by 2032, at a CAGR of 16.93% during the forecast period.

REPORT ATTRIBUTE DETAILS
Historical Period 2020-2023
Base Year 2024
Forecast Period 2025-2032
mRNA Vaccine and Therapeutics Market Size 2024 USD 13,444.94 Million
mRNA Vaccine and Therapeutics Market, CAGR 16.93%
mRNA Vaccine and Therapeutics Market Size 2032 USD 46,668.48 Million

The market growth is driven by the rising prevalence of infectious and chronic diseases, advancements in genetic research, and growing investments in biotechnology. Increasing demand for precision medicine and personalized treatments has accelerated mRNA-based therapeutic development. Rapid approvals of COVID-19 vaccines have also boosted confidence in mRNA platforms, encouraging pharmaceutical firms to expand research into cancer immunotherapy, rare genetic disorders, and autoimmune diseases.

North America leads the Global mRNA Vaccine and Therapeutics Market due to strong R&D infrastructure, robust funding, and the presence of major biotech players. Europe follows with supportive regulatory frameworks and a focus on next-generation vaccine development. The Asia-Pacific region is emerging rapidly, supported by government initiatives, expanding healthcare access, and increasing biotech investments, especially in countries like China, Japan, and India.

Global mRNA Vaccine and Therapeutics Market SizemRNA Vaccine and Therapeutics Market Insights:

  • The Global mRNA Vaccine and Therapeutics Market size was valued at USD 7,800 million in 2018, reached USD 13,444.94 million in 2024, and is projected to attain USD 46,668.48 million by 2032, growing at a CAGR of 16.93%.
  • North America held the largest share at 39.8%, supported by strong biotechnology infrastructure and the presence of key players. Europe followed with 21.3%, driven by supportive regulatory systems, while Asia Pacific captured 26.5% due to expanding vaccine research and healthcare modernization.
  • Asia Pacific emerged as the fastest-growing region, fueled by government funding, local mRNA research, and increased healthcare investments in countries such as China, Japan, and India.
  • In 2024, hospitals and clinics accounted for around 47% of the end-use segment, supported by large-scale vaccination programs and clinical integration of mRNA therapies.
  • Research organizations held nearly 35% share, reflecting strong academic collaboration and growing investment in mRNA-based oncology and infectious disease studies.

mRNA Vaccine and Therapeutics Market Drivers:

Growing Application of mRNA in Infectious and Chronic Disease Treatment

The Global mRNA Vaccine and Therapeutics Market is witnessing rapid expansion due to its broad applications in infectious and chronic disease management. Pharmaceutical companies are actively developing mRNA-based solutions for conditions like influenza, HIV, and cancer. mRNA platforms allow faster production timelines, reducing dependency on traditional vaccine models. Strong pipeline products and successful clinical trials are improving investor confidence. The growing awareness of personalized medicine is creating new treatment pathways. Technological progress in lipid nanoparticles is improving delivery efficiency. It is transforming therapeutic outcomes and expanding treatment accessibility globally. Rising healthcare investments continue to strengthen research and innovation in this field.

  • For instance, Moderna’s mRNA-1083 influenza vaccine achieved a higher antibody response in over 8,000 Phase 3 trial participants compared to standard flu vaccines, as published in June 2024 results.

Technological Innovations Enhancing Drug Delivery Efficiency and Stability

Continuous technological innovation is a major driver in the Global mRNA Vaccine and Therapeutics Market. Advances in lipid nanoparticle carriers and encapsulation methods have improved mRNA stability and bioavailability. Research in cold-chain management and thermostable formulations is making vaccines more practical for large-scale distribution. Strong collaboration between biotech firms and research institutions is accelerating development. The integration of AI and computational biology is improving sequence design and reducing time to market. It is enabling precise targeting of cells for enhanced therapeutic outcomes. Governments and private investors are supporting innovation through funding and policy backing. These developments are ensuring the reliability and scalability of mRNA-based therapies.

  • For instance, research published in a March 2023 peer-reviewed journal demonstrated that optimally lyophilized (freeze-dried) mRNA lipid nanoparticles (LNPs) could maintain their transfection efficiency when stored at room temperature (22°C) for at least 12 weeks (three months), offering a potential solution to the cold-chain limitation of existing liquid mRNA vaccines. This study, while promising, was a general academic research effort and did not specifically confirm a BioNTech product has this shelf life.

Growing Investment and Funding from Public and Private Sectors

The market is benefiting from strong financial support across global economies. Major funding initiatives from governments and private investors are fueling mRNA research and commercialization. It is helping companies expand manufacturing capabilities and clinical infrastructure. Pharmaceutical giants are entering strategic alliances to strengthen product portfolios. Academic institutions are also contributing to research diversity through collaborative studies. The increased capital flow ensures faster transition from laboratory discoveries to market-ready therapies. This support is driving long-term sustainability and encouraging smaller biotech startups to innovate. The trend highlights growing confidence in the mRNA platform’s therapeutic potential.

Expanding Scope in Oncology and Rare Disease Therapeutics

Oncology and rare disease treatments are emerging as pivotal areas for mRNA innovation. Researchers are exploring mRNA-based cancer vaccines to trigger immune responses against tumor cells. Personalized vaccines targeting specific tumor mutations are gaining attention. It is creating opportunities for precision medicine and immune-modulating therapies. Rare genetic disorders are also being targeted using mRNA technologies. The ability to code specific proteins helps treat enzyme deficiencies and metabolic conditions. Strong patent activity and collaborations are supporting drug development pipelines. These advancements are expanding the therapeutic scope and improving long-term market resilience.

Adoption of Personalized and Precision Medicine Approaches in Healthcare Systems

The Global mRNA Vaccine and Therapeutics Market is evolving toward personalized medicine, focusing on patient-specific treatment solutions. Healthcare systems are integrating genomic data and AI-driven tools for therapy customization. It is helping clinicians design targeted therapies with fewer side effects. Pharmaceutical companies are expanding genetic profiling programs to optimize vaccine efficiency. This trend aligns with the shift toward precision-based medical practices. Hospitals and research labs are adopting genomic databases for real-time diagnosis. The growing patient demand for effective and faster treatments is strengthening this transition. It is positioning mRNA therapeutics as a leading tool for personalized healthcare solutions.

  • For instance, Gritstone Bio's April 2024 presentation at the AACR Annual Meeting showcased that improvements to its proprietary AI-driven EDGE™ platform resulted in a field-leading HLA Class I prediction accuracy of over 80%. This was an internal R&D achievement and not the result of a 2024 partnership with CureVac, which has its own separate collaborations for neoantigen identification.

Rising Collaborations Between Biotech Firms and Pharmaceutical Companies

Strategic collaborations are shaping innovation in the Global mRNA Vaccine and Therapeutics Market. Partnerships between biotech and pharmaceutical firms are accelerating drug development and clinical validation. Co-development models are reducing time and cost barriers in vaccine production. Governments are supporting public-private collaborations to scale R&D infrastructure. It is helping companies overcome technical challenges and improve global access. Mergers and acquisitions are expanding market reach and portfolio diversity. The collaboration trend is fostering shared knowledge and technical expertise. It is enhancing innovation pipelines and promoting cross-border research integration.

  • For instance, Sanofi and BioNTech’s existing collaboration for cancer immunotherapies, which began in November 2015 and was expanded in January 2019, successfully moved their first candidate from concept to clinical stage in "well under three years". Separately, in May 2024, Sanofi announced a new licensing agreement with Novavax for a protein-based flu-COVID combination vaccine, a strategy that moves away from mRNA technology for their influenza portfolio.

Increasing Focus on Non-Vaccine Therapeutic Applications

The market is shifting focus beyond vaccines toward therapeutic use cases such as oncology and regenerative medicine. The Global mRNA Vaccine and Therapeutics Market is exploring mRNA’s role in protein replacement and immune modulation. It is offering new possibilities for genetic and autoimmune disorders. Research into mRNA therapies for cardiovascular and metabolic diseases is expanding. The trend highlights the potential to replace traditional biologics with faster, scalable alternatives. Biotech companies are investing in long-term platforms for multi-disease targeting. Continuous advancements in mRNA design and delivery are improving therapeutic precision. This transition is redefining the future of biopharmaceutical innovation.

Growing Demand for Scalable Manufacturing and Supply Chain Modernization

The expansion of mRNA production capacity is a key trend driving global competitiveness. The Global mRNA Vaccine and Therapeutics Market is experiencing strong investment in modular and automated manufacturing facilities. It is addressing scalability issues faced during pandemic responses. Companies are integrating robotics and AI to optimize yield and quality control. Governments are supporting domestic production to reduce import reliance. Global supply chain networks are adapting to cold-chain requirements with advanced logistics. The modernization of manufacturing systems ensures rapid response capability for emerging health threats. It is building resilience and long-term efficiency in biopharmaceutical production.

mRNA Vaccine and Therapeutics Market Challenges Analysis:

Regulatory Complexity and Standardization Issues Across Global Regions

The Global mRNA Vaccine and Therapeutics Market faces complex regulatory frameworks that slow product approvals. Differences in national guidelines for genetic materials, clinical testing, and quality control create inconsistency. Regulatory harmonization remains limited, leading to delays in commercialization. It is challenging for small and mid-sized companies to meet stringent safety and efficacy standards. High compliance costs add further burden to development timelines. The rapid pace of mRNA innovation often outpaces existing regulatory frameworks. Limited awareness among regulators regarding emerging mRNA technologies increases review times. Coordinated international efforts are needed to simplify approval pathways and promote transparency.

Manufacturing Costs, Cold Chain Constraints, and Workforce Shortages

Manufacturing complexity continues to challenge the scalability of mRNA products. The Global mRNA Vaccine and Therapeutics Market is dealing with high costs for specialized equipment, raw materials, and temperature-controlled logistics. Cold-chain infrastructure gaps restrict global distribution, especially in low-income nations. Skilled workforce shortages in molecular biology and RNA engineering further limit capacity expansion. It is difficult for emerging companies to maintain cost efficiency while ensuring quality. Energy-intensive production processes contribute to operational challenges. The need for automation and process optimization is becoming critical. Addressing these limitations will determine the market’s long-term growth and accessibility.

mRNA Vaccine and Therapeutics Market Opportunities:

Expansion into Cancer Immunotherapy and Genetic Disorder Treatments

The Global mRNA Vaccine and Therapeutics Market offers major opportunities in oncology and genetic medicine. The flexibility of mRNA enables rapid design of tumor-specific vaccines, improving patient response rates. It is also opening potential in treating genetic deficiencies through protein synthesis. Advances in lipid nanoparticles and vector design are improving delivery success in complex tissues. Collaborations between biotech firms and cancer research institutes are growing. These factors are enhancing the clinical pipeline for next-generation therapeutics. The expanding role of mRNA platforms is likely to reshape precision treatment landscapes worldwide.

Rising Government Support and Global Health Preparedness Initiatives

Governments and health organizations are prioritizing mRNA technologies for future pandemic readiness. The Global mRNA Vaccine and Therapeutics Market is gaining policy-driven momentum through funding and capacity-building programs. It is attracting public-private partnerships aimed at expanding regional production hubs. National strategies promoting local manufacturing and research autonomy are accelerating adoption. The focus on self-reliance and resilient healthcare systems is creating strong growth prospects. Public investment in cold-chain infrastructure and technology transfer initiatives is improving global accessibility. These developments are fostering innovation, preparedness, and equitable health outcomes.

Global mRNA Vaccine and Therapeutics Market Seg

mRNA Vaccine and Therapeutics Market Segmentation Analysis:

By Type

The Global mRNA Vaccine and Therapeutics Market is divided into prophylactic and therapeutic segments. Prophylactic mRNA vaccines hold a dominant share due to their successful use in preventing infectious diseases such as COVID-19 and influenza. Continuous innovation in vaccine delivery platforms supports their sustained demand. The therapeutic segment is gaining traction with growing research in cancer immunotherapy, rare genetic disorders, and metabolic diseases. It benefits from the ability of mRNA technology to encode specific proteins for targeted therapy. The shift toward chronic disease management is accelerating investment in therapeutic applications.

  • For instance, Sanofi and Translate Bio's mRNA therapy for cystic fibrosis (MRT5005) demonstrated robust dose-dependent delivery and expression of human CFTR mRNA and protein in animal studies (specifically rats and nonhuman primates), with mRNA levels in the lungs increasing up to 1500-fold compared to endogenous levels.

By End-Use

Hospitals and clinics lead the end-use segment owing to their role in vaccination programs and advanced treatment delivery. Strong healthcare infrastructure and expanding immunization coverage drive their dominance. Research organizations follow closely, supported by active R&D funding and academic collaborations. It is fostering breakthroughs in personalized and precision medicine. The “Others” category, including contract manufacturing and biotech startups, is emerging through specialized drug development initiatives.

By Application

Infectious diseases represent the largest application segment, supported by rising global health challenges and preventive immunization campaigns. Oncology is emerging rapidly as mRNA-based cancer vaccines enter clinical pipelines. Rare genetic diseases and respiratory disorders also show promising potential due to ongoing advancements in targeted gene therapy. The “Others” segment covers autoimmune and cardiovascular conditions, reflecting the broadening therapeutic potential of mRNA technology. It highlights the adaptability of this platform across multiple medical domains.

Global mRNA Vaccine and Therapeutics Market Seg1

Segmentation:

By Type

  • Prophylactic
  • Therapeutic

By End-Use

  • Hospitals & Clinics
  • Research Organizations
  • Others

By Application

  • Infectious Diseases
  • Oncology
  • Rare Genetic Diseases
  • Respiratory Diseases
  • Others

By Region

  • North America
    • S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East
    • GCC Countries
    • Israel
    • Turkey
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Rest of Africa

Regional Analysis:

North America

The North America Global mRNA Vaccine and Therapeutics Market size was valued at USD 3,137.94 million in 2018 to USD 5,349.66 million in 2024 and is anticipated to reach USD 18,546.14 million by 2032, at a CAGR of 16.9% during the forecast period. North America dominates the global market, accounting for the largest share due to advanced healthcare infrastructure, robust biotechnology R&D, and high adoption of novel therapeutics. It benefits from strong government funding, well-established clinical trial networks, and the presence of key players such as Moderna and Pfizer. Continuous product innovation and collaboration between pharmaceutical and academic institutions are accelerating research in cancer and infectious disease applications. Favorable regulatory frameworks and rapid approval mechanisms strengthen market penetration. The region’s emphasis on vaccine manufacturing and innovation leadership supports sustained growth in the coming years.

Europe

The Europe Global mRNA Vaccine and Therapeutics Market size was valued at USD 1,739.40 million in 2018 to USD 2,860.72 million in 2024 and is anticipated to reach USD 9,275.49 million by 2032, at a CAGR of 15.9% during the forecast period. Europe holds a substantial market share due to active participation of companies such as BioNTech and CureVac. It benefits from strong research institutions and supportive regulatory bodies like the EMA promoting biotechnology advancements. Public-private collaborations are driving vaccine development and cancer immunotherapy research. Countries such as Germany, the UK, and France are key contributors to regional growth. It is also witnessing rising investment in precision medicine and biomanufacturing. The focus on developing regional supply chains and sustainable healthcare strategies reinforces its leadership in biotechnology innovation.

Asia Pacific

The Asia Pacific Global mRNA Vaccine and Therapeutics Market size was valued at USD 1,981.20 million in 2018 to USD 3,560.84 million in 2024 and is anticipated to reach USD 13,594.57 million by 2032, at a CAGR of 18.3% during the forecast period. Asia Pacific represents the fastest-growing regional market, driven by expanding healthcare infrastructure, government funding, and local manufacturing capacity. Countries such as China, Japan, and India are investing heavily in biotechnology and vaccine development. Growing awareness of preventive healthcare and rising chronic disease prevalence support mRNA adoption. The region’s cost-effective clinical trials and supportive regulatory frameworks encourage multinational companies to establish partnerships. It is emerging as a vital hub for clinical research, vaccine innovation, and large-scale production. Rapid technological advancement and favorable demographic factors will continue to boost regional expansion.

Latin America

The Latin America Global mRNA Vaccine and Therapeutics Market size was valued at USD 553.80 million in 2018 to USD 946.39 million in 2024 and is anticipated to reach USD 3,074.05 million by 2032, at a CAGR of 16.0% during the forecast period. Latin America is gradually expanding its market presence through public health initiatives and vaccination programs. Brazil and Mexico are key markets, supported by investments in biotechnology and clinical research. The growing burden of infectious diseases and government-led healthcare reforms are creating favorable conditions for adoption. It is also benefiting from regional collaborations with global pharmaceutical players for vaccine distribution. Improvements in healthcare access and diagnostic capabilities are strengthening demand for innovative therapies. Latin America’s young population and increasing R&D spending position it as an emerging growth region.

Middle East

The Middle East Global mRNA Vaccine and Therapeutics Market size was valued at USD 241.80 million in 2018 to USD 384.44 million in 2024 and is anticipated to reach USD 1,171.64 million by 2032, at a CAGR of 15.1% during the forecast period. The region’s market is expanding due to increasing healthcare modernization and growing investments in life sciences. GCC countries are leading growth with strategic national vaccination programs and biomedical research investments. It is witnessing partnerships with global biotech firms to develop regional manufacturing capacity. Government initiatives supporting local production and R&D diversification are fueling development. The rising prevalence of chronic diseases and rising awareness of preventive healthcare are driving market uptake. Continuous improvements in logistics and cold-chain infrastructure are enhancing accessibility to mRNA-based products.

Africa

The Africa Global mRNA Vaccine and Therapeutics Market size was valued at USD 145.86 million in 2018 to USD 342.90 million in 2024 and is anticipated to reach USD 1,006.60 million by 2032, at a CAGR of 14.0% during the forecast period. Africa’s market share remains smaller but is gaining attention through vaccine equity programs and international partnerships. It is witnessing progress in healthcare infrastructure and biotechnology education. Countries such as South Africa and Egypt are leading regional efforts in vaccine research and production. Collaborations with WHO and global health organizations are improving access to advanced therapeutics. Growing demand for immunization and disease control initiatives supports gradual market penetration. The region’s increasing investment in local manufacturing capabilities and cold-chain systems enhances readiness for future mRNA deployment.

Key Player Analysis:

  • Moderna Inc.
  • BioNTech SE
  • CureVac N.V.
  • Arcturus Therapeutics
  • Sanofi
  • GSK Plc.
  • Argos Therapeutics Inc.
  • Ethris
  • Pfizer Inc.
  • AstraZeneca

Competitive Analysis:

The Global mRNA Vaccine and Therapeutics Market is highly competitive, driven by innovation, research intensity, and strategic alliances. Leading companies such as Moderna, BioNTech, Pfizer, and CureVac dominate through strong product portfolios and R&D investment. It is characterized by rapid clinical advancements and patent-driven competition across vaccine and therapeutic pipelines. Partnerships with academic institutions and government funding programs strengthen their research base. Smaller biotech firms are entering the market with niche products targeting cancer and rare genetic disorders. Companies focus on expanding global manufacturing capacity and distribution networks. Continuous improvements in lipid nanoparticles and formulation technologies enhance product differentiation and long-term competitiveness.

Recent Developments:

  • In October 2025, Moderna Inc. officially announced discontinuation of development for its investigational CMV vaccine, mRNA-1647, after the pivotal Phase 3 trial did not meet the efficacy endpoint, marking a setback for one of their key late-stage pipeline assets.
  • In October 2025, BioNTech SE continued integrating advanced artificial intelligence into its mRNA discovery pipeline, co-hosting its second AI Day event in London together with InstaDeep Ltd., to showcase AI applications across vaccine and therapeutics development.
  • In June–October 2025, CureVac N.V. entered into a binding agreement to be acquired by BioNTech SE for $1.25 billion, strengthening BioNTech’s mRNA cancer immunotherapy portfolio.

Report Coverage:

The research report offers an in-depth analysis based on type, end-use, and application segments. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

  • Continued investment in mRNA technology will expand vaccine and therapeutic pipelines.
  • Cancer immunotherapy is expected to emerge as a key growth driver.
  • Regional manufacturing hubs will strengthen supply chain resilience.
  • AI and bioinformatics will improve mRNA design and sequence optimization.
  • Partnerships between pharma and biotech firms will increase innovation speed.
  • Advancements in lipid nanoparticles will improve delivery efficiency.
  • Demand for mRNA-based treatments in rare diseases will grow steadily.
  • Regulatory harmonization will enhance approval timelines globally.
  • Expansion into non-vaccine applications will diversify revenue sources.
  • Public and private funding will sustain long-term R&D activities.
mRNA Vaccine and Therapeutics Market Size and Report 2032
Report Attribute Details
Details
Historical Period
-
Base Year
2018
Forecast Period
2018–2032
mRNA Vaccine and Therapeutics Size 2018
USD 7,800 million
mRNA Vaccine and Therapeutics CAGR
16.93%
mRNA Vaccine and Therapeutics Size 2032
USD 46,668.48 million

Request a Free Sample

Fill in your details and we'll send you a free sample report.

  • Sample data tables & charts
  • Research methodology

Market Dynamics

Expanding Application in Infectious and Chronic Disease Treatment

The versatility of mRNA platforms enables rapid development of vaccines and therapeutics for a wide range of infectious and chronic diseases, including influenza, HIV, and cancer. This adaptability is accelerating product pipelines and attracting significant investment from pharmaceutical companies.

Technological Innovations in Drug Delivery and Stability

Advances in lipid nanoparticle carriers, encapsulation methods, and thermostable formulations are improving the stability, bioavailability, and distribution of mRNA products. These innovations are making large-scale deployment more feasible and expanding the market’s reach.

Growing Investment and Funding from Public and Private Sectors

Robust financial support from governments, venture capital, and pharmaceutical giants is fueling R&D, manufacturing expansion, and clinical trials. This influx of capital is enabling both established firms and startups to accelerate innovation and commercialization.

Rising Demand for Personalized and Precision Medicine

Healthcare systems are increasingly adopting personalized medicine approaches, leveraging mRNA’s ability to create patient-specific therapies with improved efficacy and fewer side effects. This trend is driving the integration of mRNA technologies into oncology, rare diseases, and other targeted applications.

Strategic Collaborations and Partnerships

Collaborations between biotech firms, pharmaceutical companies, and academic institutions are accelerating drug development, clinical validation, and global market access. These partnerships are reducing time-to-market and fostering innovation across the mRNA therapeutics landscape.

Need a Custom Version of This Report?

Tailor the scope, geography, or segments to your exact requirements.

  • Custom geography or segment scope
  • Direct access to our analyst team

Frequently Asked Questions

What is the current market size for Global mRNA Vaccine and Therapeutics Market, and what is its projected size in 2032?
The Global mRNA Vaccine and Therapeutics Market size was valued at USD 7,800 million in 2018 and reached USD 13,444.94 million in 2024. It is anticipated to attain USD 46,668.48 million by 2032, reflecting strong long-term growth potential.
At what Compound Annual Growth Rate is the Global mRNA Vaccine and Therapeutics Market projected to grow between 2025 and 2032?
The market is projected to grow at a CAGR of 16.93% during the forecast period. The rising adoption of mRNA-based therapies and continuous innovation in vaccine platforms are driving this growth rate.
Which Global mRNA Vaccine and Therapeutics Market segment held the largest share in 2024?
The prophylactic segment held the largest share in 2024 due to widespread demand for mRNA vaccines against infectious diseases, supported by strong public immunization initiatives and pharmaceutical investment.
What are the primary factors fueling the growth of the Global mRNA Vaccine and Therapeutics Market?
Key growth factors include increased focus on infectious disease prevention, rapid R&D advancements, supportive regulatory policies, and expansion of personalized medicine. Growing funding for biopharmaceutical innovation is further strengthening growth.
Who are the leading companies in the Global mRNA Vaccine and Therapeutics Market?
Major players include Moderna Inc., BioNTech SE, Pfizer Inc., CureVac N.V., and GSK Plc. These companies are leading innovation through product development, strategic collaborations, and global manufacturing expansion.
Which region commanded the largest share of the Global mRNA Vaccine and Therapeutics Market in 2024?
North America commanded the largest share in 2024, supported by advanced research infrastructure, strong government funding, and the presence of major biotechnology firms driving innovation and commercialization.

Table of Content

Chapter 1 Market Segmentation

  • 1.1 Segmentation Framework
    • 1.1.1 Product and Service Classification
    • 1.1.2 Application and End-Use Classification
    • 1.1.3 Technology and Solution Classification
    • 1.1.4 Customer and Distribution Channel Classification
    • 1.1.5 Geographic Segmentation
    • 1.1.6 Market Segment Definitions and Boundaries
  • 1.2 By Type
    • 1.2.1 Prophylactic
    • 1.2.2 Therapeutic
  • 1.3 By End-Use
    • 1.3.1 Hospitals & Clinics
    • 1.3.2 Research Organizations
    • 1.3.3 Others
  • 1.4 By Application
    • 1.4.1 Infectious Diseases
    • 1.4.2 Oncology
    • 1.4.3 Rare Genetic Diseases
    • 1.4.4 Respiratory Diseases
    • 1.4.5 Others

Chapter 2 Introduction

  • 2.1 Report Objectives and Scope
  • 2.2 Product Definition and Industry Terminology
  • 2.3 Market Inclusions and Exclusions
  • 2.4 Research Process
    • 2.4.1 Primary Research and Expert Interviews
    • 2.4.2 Secondary Research and Source Review
    • 2.4.3 Top-Down and Bottom-Up Estimation
    • 2.4.4 Data Triangulation and Verification
  • 2.5 Market Size Measurement Basis
    • 2.5.1 2018: USD 7,800 million → 2032: USD 46,668.48 million
  • 2.6 Historical and Forecast Reference Periods
    • 2.6.1 Base Year: 2018
    • 2.6.2 Forecast Period: 2018-2032
  • 2.7 Research Assumptions and Limitations

Chapter 3 Executive Summary

  • 3.1 Market Snapshot and Key Findings
  • 3.2 Base-Year Market Size, 2018
  • 3.3 Forecast Market Size, 2032
  • 3.4 Revenue and Volume Growth Outlook
  • 3.5 Key Demand and Supply Indicators
  • 3.6 Leading Market Segments
  • 3.7 Fastest-Growing Market Opportunities
  • 3.8 Regional Performance Highlights
  • 3.9 Technology and Industry Transformation
  • 3.10 Competitive Landscape Summary
  • 3.11 Analyst View and Strategic Implications

Chapter 4 Global mRNA Vaccine and Therapeutics Market Trends and Developments

  • 4.1 Historical Industry Development
  • 4.2 Recent Market Trends and Developments
  • 4.3 Demand and Customer Behavior Trends
  • 4.4 Technology and Product Innovation
  • 4.5 Artificial Intelligence, Automation and Digitalization
  • 4.6 Local Manufacturing and Supply Chain Realignment
  • 4.7 Industry Partnerships, Mergers and Acquisitions
  • 4.8 Sustainability and Circular Economy Developments
  • 4.9 Government and Private Sector Investment Trends
  • 4.10 Emerging Business Models and Commercialization
  • 4.11 Industry Developments and Announcements

Chapter 5 Global mRNA Vaccine and Therapeutics Market Production, Supply and Demand Analysis

  • 5.1 Demand Trend and Consumption Analysis
  • 5.2 Demand Forecast, 2018-2032
  • 5.3 Production and Output Trend
  • 5.4 Production and Output Forecast, 2018-2032
  • 5.5 Installed Capacity and Capacity Utilization
  • 5.6 Company-Wise Production Plants and Statistics
    • 5.6.1 Installed Production Capacity
    • 5.6.2 Actual Production
    • 5.6.3 Planned Capacity and Expansion Targets
  • 5.7 Supply Chain Structure and Procurement Trends
  • 5.8 Supply-Demand Gap and Bottlenecks
  • 5.9 Import Dependence and Sourcing Structure
  • 5.10 Contract Manufacturing and Outsourcing
  • 5.11 Regional Supply and Demand Concentration

Chapter 6 Global mRNA Vaccine and Therapeutics Market Pricing Analysis

  • 6.1 Pricing Structure and Measurement
  • 6.2 Historical Pricing Trends
  • 6.3 Pricing Outlook, 2018-2032
  • 6.4 Average Selling Price and Unit Economics
  • 6.5 Pricing by Product and Market Segment
  • 6.6 Geographic Pricing Differences
  • 6.7 Key Input, Energy, Labor and Logistics Costs
  • 6.8 Contract Pricing and Purchasing Models
  • 6.9 Pricing Sensitivity and Competitive Positioning
  • 6.10 Price, Margin and Profitability Implications

Chapter 7 Global mRNA Vaccine and Therapeutics Market Dynamics

  • 7.1 Market Growth Drivers
    • 7.1.1 Demand-Side Drivers
    • 7.1.2 Technology and Innovation Drivers
    • 7.1.3 Infrastructure and Investment Drivers
    • 7.1.4 Regulatory and Policy Drivers
  • 7.2 Market Restraints
    • 7.2.1 Cost and Affordability Constraints
    • 7.2.2 Technology and Adoption Barriers
    • 7.2.3 Supply Chain and Operational Constraints
  • 7.3 Market Challenges
    • 7.3.1 Competitive Pressure and Margin Erosion
    • 7.3.2 Skills, Infrastructure and Implementation Gaps
  • 7.4 Emerging Market Opportunities
  • 7.5 Market Dynamics Impact and Time-Horizon Assessment

Chapter 8 Global mRNA Vaccine and Therapeutics Value Chain Analysis

  • 8.1 Industry Value Chain Overview
  • 8.2 Upstream Suppliers and Critical Inputs
  • 8.3 Technology and Component Providers
  • 8.4 Manufacturing or Service Delivery
  • 8.5 Distribution, Channel Partners and Integrators
  • 8.6 Downstream Applications and End Users
  • 8.7 Value Addition and Profit Pools
  • 8.8 Vertical Integration and Outsourcing
  • 8.9 Supplier Concentration and Risk
  • 8.10 Supply Chain Localization and Resilience

Chapter 9 Global mRNA Vaccine and Therapeutics Market Regulations and Policies

  • 9.1 Relevant Laws, Standards and Compliance Frameworks
  • 9.2 Product, Service, Safety and Quality Requirements
  • 9.3 Government Policies, Incentives and Subsidies
  • 9.4 Imports, Exports and Trade Barriers
  • 9.5 Public Procurement and Local Content Requirements
  • 9.6 Environmental and Sustainability Compliance
  • 9.7 Upcoming Policy Changes and Market Implications

Chapter 10 Global mRNA Vaccine and Therapeutics Market Hotspots and Opportunities

  • 10.1 Market Opportunity Mapping and Growth Hotspots
  • 10.2 High-Growth Applications and Customer Groups
  • 10.3 Underserved Markets and White-Space Opportunities
  • 10.4 Emerging Technology and Product Opportunities
  • 10.5 New Capacity and Investment Hotspots
  • 10.6 Market Entry and Expansion Opportunities
  • 10.7 Distribution and Partnership Opportunities
  • 10.8 Near-Term and Long-Term Commercial Potential
  • 10.9 Opportunity Attractiveness and Execution Risks

Chapter 11 Global mRNA Vaccine and Therapeutics Market Outlook, 2018-2032

  • 11.1 Market Size and Analysis
    • 11.1.1 Revenue (Market Measurement: 2018: USD 7,800 million → 2032: USD 46,668.48 million)
    • 11.1.2 Market Volume and Quantity Sold
    • 11.1.3 Historical Market Size
    • 11.1.4 Base-Year Market Size, 2018
  • 11.2 Market Forecast, 2018-2032
    • 11.2.1 Revenue Forecast to 2032
    • 11.2.2 Volume Forecast to 2032
    • 11.2.3 CAGR and Year-on-Year Growth
    • 11.2.4 Incremental Revenue Opportunity
  • 11.3 Forecast Assumptions and Scenario Analysis
    • 11.3.1 Base-Case Forecast
    • 11.3.2 Optimistic and Conservative Scenarios
    • 11.3.3 Technology, Pricing and Policy Sensitivities
  • 11.4 Market Attractiveness and Growth Outlook

Chapter 12 Global mRNA Vaccine and Therapeutics Market Segmentation and Outlook

  • 12.1 Segmentation Summary and Market Shares, 2018
  • 12.2 Largest and Fastest-Growing Segments
  • 12.3 By Type - Market Size and Forecast, 2018-2032
    • 12.3.1 Segment Definition and Scope
    • 12.3.2 Historical Market Size
    • 12.3.3 Revenue Forecast, 2018-2032
    • 12.3.4 Volume Forecast, 2018-2032
    • 12.3.5 Base-Year Market Share, 2018
    • 12.3.6 Segment CAGR and Growth Drivers
    • 12.3.7 Subsegment Market Size and Forecast
      • 12.3.7.1 Prophylactic
      • 12.3.7.2 Therapeutic
    • 12.3.8 Subsegment Pricing and Adoption Trends
    • 12.3.9 Leading Suppliers and Competition
    • 12.3.10 Regional Demand and Opportunities
  • 12.4 By End-Use - Market Size and Forecast, 2018-2032
    • 12.4.1 Segment Definition and Scope
    • 12.4.2 Historical Market Size
    • 12.4.3 Revenue Forecast, 2018-2032
    • 12.4.4 Volume Forecast, 2018-2032
    • 12.4.5 Base-Year Market Share, 2018
    • 12.4.6 Segment CAGR and Growth Drivers
    • 12.4.7 Subsegment Market Size and Forecast
      • 12.4.7.1 Hospitals & Clinics
      • 12.4.7.2 Research Organizations
      • 12.4.7.3 Others
    • 12.4.8 Subsegment Pricing and Adoption Trends
    • 12.4.9 Leading Suppliers and Competition
    • 12.4.10 Regional Demand and Opportunities
  • 12.5 By Application - Market Size and Forecast, 2018-2032
    • 12.5.1 Segment Definition and Scope
    • 12.5.2 Historical Market Size
    • 12.5.3 Revenue Forecast, 2018-2032
    • 12.5.4 Volume Forecast, 2018-2032
    • 12.5.5 Base-Year Market Share, 2018
    • 12.5.6 Segment CAGR and Growth Drivers
    • 12.5.7 Subsegment Market Size and Forecast
      • 12.5.7.1 Infectious Diseases
      • 12.5.7.2 Oncology
      • 12.5.7.3 Rare Genetic Diseases
      • 12.5.7.4 Respiratory Diseases
      • 12.5.7.5 Others
    • 12.5.8 Subsegment Pricing and Adoption Trends
    • 12.5.9 Leading Suppliers and Competition
    • 12.5.10 Regional Demand and Opportunities
  • 12.6 Segment Growth Comparison
  • 12.7 Segment Attractiveness and Priority Matrix

Chapter 13 Global mRNA Vaccine and Therapeutics End-Use and Application Market Outlook

  • 13.1 End-Use Industry and Customer Demand Structure
  • 13.2 Leading Applications and Customer Groups
  • 13.3 End-Use Market Size, Share and Forecast
  • 13.4 Major End-Use Industry Deep Dives
    • 13.4.1 Customer Requirements and Use Cases
    • 13.4.2 Demand and Replacement Cycles
    • 13.4.3 Technical and Regulatory Considerations
    • 13.4.4 Purchasing and Procurement Models
    • 13.4.5 Leading Vendors and Distribution Channels
    • 13.4.6 Forecast and Commercial Opportunities
  • 13.5 Emerging Applications and Cross-Segment Demand
  • 13.6 End-Use Industry Investment Priorities

Chapter 14 Global mRNA Vaccine and Therapeutics Geographic Market Outlook, 2018-2032

  • 14.1 Regional Market Size and Share, 2018
  • 14.2 Regional Market Forecast, 2018-2032
  • 14.3 Regional Pricing, Production and Demand Differences
  • 14.4 North America
    • 14.4.1 United States
    • 14.4.2 Canada
    • 14.4.3 Mexico
  • 14.5 Europe
    • 14.5.1 Germany
    • 14.5.2 France
    • 14.5.3 Italy
    • 14.5.4 United Kingdom
    • 14.5.5 Spain
    • 14.5.6 Poland
    • 14.5.7 Russia
    • 14.5.8 Netherlands
    • 14.5.9 Belgium
    • 14.5.10 Sweden
    • 14.5.11 Denmark
    • 14.5.12 Norway
    • 14.5.13 Rest of Europe
  • 14.6 Asia Pacific
    • 14.6.1 China
    • 14.6.2 India
    • 14.6.3 Japan
    • 14.6.4 South Korea
    • 14.6.5 Thailand
    • 14.6.6 Indonesia
    • 14.6.7 Vietnam
    • 14.6.8 Malaysia
    • 14.6.9 Australia
    • 14.6.10 Rest of Asia Pacific
  • 14.7 Latin America
    • 14.7.1 Brazil
    • 14.7.2 Argentina
    • 14.7.3 Colombia
    • 14.7.4 Chile
    • 14.7.5 Rest of Latin America
  • 14.8 Middle East
    • 14.8.1 Saudi Arabia
    • 14.8.2 United Arab Emirates
    • 14.8.3 Turkey
    • 14.8.4 Israel
    • 14.8.5 Iran
    • 14.8.6 Rest of the Middle East
  • 14.9 Africa
    • 14.9.1 South Africa
    • 14.9.2 Egypt
    • 14.9.3 Nigeria
    • 14.9.4 Morocco
    • 14.9.5 Rest of Africa
  • 14.10 Regional Investment, Policy and Supply Chain Differences
  • 14.11 Regional Competitive Landscape
  • 14.12 Geographic Growth Hotspots

Chapter 15 Global mRNA Vaccine and Therapeutics Technology, Innovation and Sustainability Outlook

  • 15.1 Technology Landscape and Maturity
  • 15.2 Product, Process and Service Innovation
  • 15.3 AI, Automation and Digital Tools in the Industry
  • 15.4 Technology Adoption and Performance Benchmarking
  • 15.5 Innovation Pipeline and R&D Investment
  • 15.6 Patent and Intellectual Property Trends
  • 15.7 Energy Efficiency and Resource Management
  • 15.8 Sustainability, Recycling and Circularity
  • 15.9 Technology Roadmap, 2018-2032
  • 15.10 Risks of Obsolescence and Technology Substitution

Chapter 16 Global mRNA Vaccine and Therapeutics Market Key Strategic Imperatives

  • 16.1 Growth and Market Entry Priorities
  • 16.2 High-Return Products and Segments
  • 16.3 Pricing, Profitability and Cost Optimization
  • 16.4 Technology Investment and Product Differentiation
  • 16.5 Supply Chain Localization and Resilience
  • 16.6 Distribution and Customer Acquisition
  • 16.7 Partnership, Acquisition and Capacity Strategy
  • 16.8 Regional Expansion Priorities
  • 16.9 Short-, Medium- and Long-Term Actions

Chapter 17 Competition Outlook

  • 17.1 Industry Competition Characteristics
  • 17.2 Market Structure and Concentration
  • 17.3 Market Share and Competitive Positioning, 2018
  • 17.4 Company-Wise Revenue and Product Benchmarking
  • 17.5 Production and Service Capacity Benchmarking
  • 17.6 Technology, Pricing and Differentiation
  • 17.7 Regional Footprint and Distribution Strength
  • 17.8 Mergers, Acquisitions and Strategic Alliances
  • 17.9 New Entrants and Competitive Threats
  • 17.10 Porter's Five Forces and Industry Attractiveness
  • 17.11 Competitive Outlook, 2018-2032

Chapter 18 Company Profiles

  • 18.1 Company Coverage and Selection Criteria
  • 18.2 Moderna Inc.
    • 18.2.1 Business Description
    • 18.2.2 Company Ownership and Geographic Presence
    • 18.2.3 Product and Service Portfolio
    • 18.2.4 Manufacturing and Operating Footprint
    • 18.2.5 Production Capacity and Expansion Plans
    • 18.2.6 Financial Performance and Investment
    • 18.2.7 Market Share and Competitive Position
    • 18.2.8 Technology and Innovation Capabilities
    • 18.2.9 Strategic Alliances or Partnerships
    • 18.2.10 Recent Developments
    • 18.2.11 Growth Strategy and Outlook
  • 18.3 BioNTech SE
  • 18.4 CureVac N.V.
  • 18.5 Arcturus Therapeutics
  • 18.6 Sanofi
  • 18.7 GSK Plc.
  • 18.8 Pfizer Inc.
  • 18.9 AstraZeneca
  • 18.10 Ethris
  • 18.11 Argos Therapeutics Inc.
  • 18.12 Other Relevant Market Participants

Note: Every listed company is profiled on the structure shown under the first company. The company list is preliminary and may change based on research findings, market developments, data availability and client requirements.

Chapter 19 Disclaimer

  • 19.1 Research and Forecast Disclaimer
  • 19.2 Data Source and Estimation Limitations

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.

Methodology

Meet the Team

Shweta Bisht
Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

Deepti Agrawal

Reviewed by

Deepti Agrawal

Head of Editorial Operations

Related Topics

Biochemistry Analyzers Market Size, Share, Growth and Forecast, 2025-2035

Biochemistry analyzers market worth USD 5.41 billion in 2025 is set to reach USD 9.87 billion by 2035 at a 6.20% CAGR as labs automate and consolidate

Thoracolumbar Spine Devices Market Size, Share, Growth and Forecast, 2025-2035

Thoracolumbar spine devices market worth USD 4.09 billion in 2025 reaches USD 6.12 billion by 2035, at a 4.10% CAGR as fusion moves to navigated care.

US Pharmacy Automation Market Size, Share, Growth and Forecast, 2025-2035

U.S. pharmacy automation market worth USD 3.21 billion in 2025 is forecast to reach USD 6.78 billion by 2035 at a 7.78% CAGR as staffing gaps push robotics.

Cardiopulmonary Bypass System Market Size, Share, Growth and Forecast, 2025-2035

Cardiopulmonary bypass system market worth USD 220.2 million in 2025 will reach USD 316.6 million by 2035, at a 3.70% CAGR, as consoles are replaced.

South Korea Cardiovascular Devices Market Size, Share, Growth and Forecast, 2025-2035

South Korea cardiovascular devices market worth USD 1.34 billion in 2025 will reach USD 2.59 billion by 2035 at a 6.80% CAGR as aging lifts TAVI and ablation.

Diabetes Drugs Market Size, Share, Growth and Forecast, 2025-2035

Diabetes drugs market worth USD 116.65 billion in 2025 is forecast to reach USD 228.14 billion by 2035, rising at a 6.94% CAGR as incretin use widens.